Long-term low-dose tolvaptan efficacy and safety in SIADH

PURPOSE: Tolvaptan, a selective vasopressin V2-receptor antagonist, is approved for the treatment of SIADH-related hyponatremia, but its use is limited. The starting dose is usually 15 mg/day, but recent clinical experience suggests a lower starting dose (<15 mg/day) to reduce the risk of sodium...

Descripción completa

Detalles Bibliográficos
Autores principales: Bondanelli, Marta, Aliberti, Ludovica, Gagliardi, Irene, Ambrosio, Maria Rosaria, Zatelli, Maria Chiara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543144/
https://www.ncbi.nlm.nih.gov/pubmed/37507553
http://dx.doi.org/10.1007/s12020-023-03457-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543144/
https://www.ncbi.nlm.nih.gov/pubmed/37507553
http://dx.doi.org/10.1007/s12020-023-03457-w

Ejemplares similares